ENVB
Enveric Biosciences Inc

14,016
Mkt Cap
$3.91M
Volume
0.00
52W High
$8.25
52W Low
$0.5606
PE Ratio
-0.06
ENVB Fundamentals
50D MA
$0.8568
Beta
1.28
Avg. Volume
598,135.33
EPS (Annual)
-$19.04
P/B
0.87
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Enveric Biosciences Announces Reverse Stock Split
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders...
Business Wire·2d ago
News Placeholder
More News
News Placeholder
Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders...
Business Wire·9d ago
News Placeholder
Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders...
Business Wire·10d ago
News Placeholder
Enveric Biosciences to Explore Digital Asset Treasury Opportunities
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders...
Business Wire·11d ago
News Placeholder
Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of...
Business Wire·8mo ago
News Placeholder
Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of...
Business Wire·9mo ago
News Placeholder
Enveric Biosciences Announces Closing of $5 Million Public Offering
Enveric Biosciences, Inc. (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of...
Business Wire·9mo ago
News Placeholder
Enveric Biosciences Announces Pricing of $5 Million Public Offering
Enveric Biosciences, Inc. (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of...
Business Wire·9mo ago
News Placeholder
Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of...
Business Wire·9mo ago
News Placeholder
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During J.P. Morgan Week 2025
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety...
Business Wire·10mo ago

Latest ENVB News

View

Advertisement|Remove ads.

Advertisement|Remove ads.